Inactive Instrument

Press Releases Prevail Therapeutics Inc.

Equities

PRVL

US74140Y1010

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Eli Lilly and Company : - Lilly Completes Acquisition of Prevail Therapeutics	21-01-25	AQ
PREVAIL THERAPEUTICS INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	21-01-22	AQ
Prevail Therapeutics : Lilly Completes Acquisition of Prevail Therapeutics	21-01-22	PR
Eli Lilly and Company : - Lilly Announces Agreement to Acquire Prevail Therapeutics	20-12-16	AQ
PREVAIL THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	20-12-15	AQ
Prevail Therapeutics : Lilly Announces Agreement to Acquire Prevail Therapeutics	20-12-15	PR
Prevail Therapeutics : Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006	20-12-14	AQ
Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations	20-12-11	GL
Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia	20-11-30	GL
Prevail Therapeutics : Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia	20-11-30	AQ
Prevail Therapeutics : Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001	20-11-19	AQ
Prevail Therapeutics : Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001	20-11-18	AQ
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001	20-11-18	GL
Prevail Therapeutics : Reports Third Quarter 2020 Financial Results and Business Highlights	20-11-16	AQ
PREVAIL THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	20-11-13	AQ
Prevail Therapeutics : Reports Third Quarter 2020 Financial Results and Business Highlights	20-11-13	AQ
Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights	20-11-13	GL
PREVAIL THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	20-11-12	AQ
Prevail Therapeutics : to Present at Upcoming Investor Conferences	20-11-11	AQ
Prevail Therapeutics : to Present at Upcoming Investor Conferences	20-11-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Prevail Therapeutics Inc.

Equities

PRVL

US74140Y1010

Press Releases

Filters